Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biotechnology Executives Write President, Arguing Immigration Ban Strikes at U.S. Medical Innovation and Patients

Washington, DC, February 9, 2017 — Carolyn Y. Johnson reports in The Washington Post that more than 160 leaders of biotechnology companies signed a strong letter of opposition to President Donald J. Trump’s travel ban, arguing the “poorly conceived and implemented” action strikes at the heart of an industry that originated in America, has been dominated by American companies and is at the cutting edge of medicine.

The letter, published Tuesday by the journal Nature Biotechnology, reveals that scientists abroad are afraid to come to the U.S. and are canceling trips.

Foreign-born scientists within the U.S. fear similar orders could be issued without warning, and some have expressed anxiety about deportation or losing family ties.  Ultimately, the letter argues, the policy will harm patients and the U.S. economy.

“Though the ban from the Trump administration is aimed at seven countries, our global employees interpret the underlying message as, ‘America is no longer welcoming of any immigrants, whatsoever,’” wrote chief executives, venture capitalists, academic leaders and at least one Nobel Prize winner.

“If this misguided policy is not reversed, America is at risk of losing its leadership position in one of its most important sectors, one that will shape the world in the twenty-first century.”

The letter, a grass-roots effort organized late last week by a half dozen chief executives, comes in stark contrast to the tone that the leaders of major pharmaceutical companies set in a meeting last week with Trump.

Pharmaceutical leaders came away from that meeting emphasizing the common ground they had with Trump on many issues. It was unclear whether the travel ban was discussed in the private portion of the meeting.

However, in the run-up, the industry’s major trade group did not take a position and the companies that did respond were often supportive of employees, but neutral.

Biotech is a relatively young industry born from the emerging understanding of genetic science in the 1970s, best known for complex, expensive drugs created by living organisms.

As science has advanced, biotech has become an increasingly broad term for the research-driven, startup-heavy wing of the drug industry trying to turn cutting-edge science into new medicines.

As the research and development pipelines of traditional drug companies have dried up, biotech has become increasingly important — economically and to the development of new medicines.

For Johnson’s full story, click here.